Vanta™ SCS gives you an advantage over pain. This revolutionary recharge-free device offers optimized longevity, personalized programming, and unmatched MRI access.Download Brochure
Learn about Vanta™ SCS.
High-performance recharge-free neurostimulator
Vanta™ SCS is a high-performance recharge-free device offering optimized longevity.
DTM™ SCS endurance therapy
DTM™ SCS endurance therapy is an energy modified differential target multiplexed therapy offering meaningful pain relief, satisfaction, and quality of life improvements.2
Clinical evidence for DTM™ SCS endurance therapy:
Meaningful pain relief
reduction in VAS for
overall pain from
baseline to 6-months
Quality of life improvements
had minimal to moderate disability at 3-months compared to only 16% at baseline
of patients were
very or somewhat
satisfied with therapy
Creating new connections
The Medtronic adaptor extension creates a connection between certain Boston Scientific™ or Nevro™ leads.§ This enables patients with existing leads to gain access to meaningful pain relief with DTM™ SCS endurance therapy offered with recharge-free convenience on Vanta™ INS or rapid recharge on Intellis™ INS.2 Patients with an Intellis™ INS may also choose superior pain relief with DTM™ SCS therapy.4
|Width||1.1 cm (.44in)|
Settings used from Proclaim™ clinician manual. Nominal settings 12 hours per day: 50-Hz frequency. 225-μs pulse width, and 5-mA amplitude at 500-ohms impedance. Compared to flagship model 3660.
Settings from Boston Scientific's Alpha™ IFU. Programmed at 4.1mA, 280us. 40Hz. 1 area, 730 Ohms, 2 contacts.
Under specific conditions. Refer to product labeling for full list of conditions. Patients with non-Medtronic leads and an EMBSNV20 adaptor extension are not eligible for an MRI.
Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.
Provenzano, Amirdelfan, Grewal, et al. Modeling the impact of a differential target multiplexed derivative on rechargeable and recharge-free spinal cord stimulation systems using results from the Endurance Study. Poster presented at: International Neuromodulation Society (INS) World Congress; May 21-26, 2022; Barcelona, Spain.
Peacock, Provenzano, Fishman, et al. A prospective multi-center study of a differential target multiplexed™ stimulation derivative in therapy-naive patients. Poster presented at: International Neuromodulation Society (INS) World Congress; May 21-26, 2022; Barcelona, Spain.
Desai MJ, Hargens LM, Breitenfeldt MD, et al. The rate of magnetic resonance imaging in patients with spinal cord stimulation. Spine. 2015;40(9):E531–537
Fishman M. Cordner H, Justiz R. et al. 12-Month Results from mu!ticenter, open-label. randomized controlled clmical trial comparing differential target multiplexed spinal cord stimulation and traditional spinal cord stimulation in subjects with chronic intractable back pain and leg pain. Pain Pract. 2021; 00: 1–12. doi: 10.1111/papr.1 3066.